

Comparative Effects Profile: IV vs. Extended Duration Methods like Iontophoresis

Immediate Spike (IV Administration)

1. Pharmacokinetics

- **Absorption:** Immediate 100% bioavailability.
- **Half-Life:** Short, typically around 2 hours. This means that the immediate spike will be metabolized relatively quickly.

2. Pharmacodynamics

- **Immediate Activation:** Rapid engagement with target enzymes and pathways, such as sirtuins and PARPs.

3. Potential Adverse Effects

- **Hypotension:** Immediate risk due to rapid dilatation of blood vessels.
- **Electrolyte Imbalance:** Rapid shifts possible, requiring immediate corrective measures.

4. Clinical Implications

- **Monitoring:** Requires real-time monitoring of vitals and electrolytes.
- **Patient Selection:** Not suitable for those with compromised cardiovascular or renal function.

Extended Duration (Iontophoresis Patch)

1. Pharmacokinetics

- **Absorption:** Controlled release over 8+ hours.
- **Half-Life:** The extended release aligns better with the short half-life, providing a more sustained level of NAD⁺.

2. Pharmacodynamics

- **Sustained Activation:** Allows for a more prolonged engagement with target enzymes, potentially leading to more sustained therapeutic effects.

3. Potential Adverse Effects

- **Hypotension:** Lower risk due to gradual release.
- **Electrolyte Imbalance:** Less likely to cause rapid shifts, allowing for easier management.

4. Clinical Implications

- **Patient Selection:** More suitable for a broader range of patients, including those with certain pre-existing conditions.

Half-Life as a Factor

- **IV:** The short half-life of NAD⁺ means that the immediate spike will be metabolized quickly, potentially reducing the duration of any therapeutic effects but also limiting the duration of adverse effects.
- **Iontophoresis:** The extended release over 8 hours aligns better with NAD⁺'s short half-life, providing a more sustained therapeutic level and potentially reducing the frequency of administration.